Synthesis and evaluation of biodegradable PCL/PEG nanoparticles for neuroendocrine tumor targeted delivery of somatostatin analog

Drug Delivery

Volumn 19, Issue 3, 2012, Pages 132-142

  Dubey, Nazneen ^a   Varshney, Raunak ^b   Shukla, Jaya ^c   Ganeshpurkar, Aditya ^d   Hazari, Puja P ^b   Bandopadhaya, Guru P ^c   Mishra, Anil K ^b   Trivedi, Piyush ^a  

^a Drug Discovery Laboratory   (India)

^b INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

^c ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^d Shri Ram Institute of Technology   (India)

Author keywords

nanoparticles; neuroendocrine pancreatic tumors; Octreotide; PCL; targeting

Indexed keywords

MACROGOL; NANOPARTICLE; OCTREOTIDE; POLYCAPROLACTONE; SOMATOSTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIODEGRADABILITY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DIFFERENTIAL SCANNING CALORIMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; ISOTOPE LABELING; MOUSE; NEUROENDOCRINE TUMOR; NONHUMAN; PANCREAS TUMOR; PARTICLE SIZE; PEPTIDE SYNTHESIS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RECEPTOR BINDING; SOLID PHASE SYNTHESIS; SYNTHESIS; TRANSMISSION ELECTRON MICROSCOPY; TUMOR GROWTH; TUMOR REGRESSION; ZETA POTENTIAL;

ANIMALS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; ETHYLENE OXIDE; HUMANS; LACTONES; MICE; MICE, INBRED BALB C; NANOPARTICLES; NEUROENDOCRINE TUMORS; OCTREOTIDE; SOLID-PHASE SYNTHESIS TECHNIQUES; SOMATOSTATIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84858696628     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2012.657718     Document Type: Article

References (47)

1. Ain KB, Taylor KD, Tofiq S, Venkataraman G. (1997). Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines. J Clin Endocrinol Metab, 82, 1857-1862. (Pubitemid 127495200)
2. Bakker WH, Kreening EP, Breeman WAP. (1991). In vivo use of a radiolabelled somatostatin analog: dynamics. Metabolism and binding to somatostatin receptor-positive tumors in man. J Nucl Med, 3, 652-658.
3. Bodmer D, Kissel T, Traechslin E. (1992). Factors influencing the release of peptides and proteins from biodegradable parenteral depot systems. J Control Release, 21, 129-138.
4. Bruns C, Stolz B, Raulf F, Schloss J, Weckbecker G. (1997). Somatostatin receptor expression: therapeutic considerations. J Endocrinol Investig, 20 (Suppl. 7), 2-4.
5. Chanana M, Mao Z, Wang D. (2009). Using polymers to make up magnetic nanoparticles for biomedicine. J Biomed Nanotechnol, 5, 652-668.
6. Chawla JS, Amiji MM. (2002). Biodegradable poly(epsilon-caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen. Int J Pharm, 249, 127-138. (Pubitemid 35333439)
7. Davda J, Labhasetwar V. (2002). Characterization of nanoparticle uptake by endothelial cells. Int J Pharm, 233, 51-59. (Pubitemid 34230418)
8. Dubernet C. (1995).Thermoanalysis of microspheres. Thermochim Acta, 248, 259-269.
9. Fisher WE, Muscarella P, O'Dorisio TM, O'Dorisio MS, Kim JA, Doran TA, Sabourin CL, Schirmer WJ. (1996). Expression of the somatostatin receptor subtype-2 gene predicts response of human pancreatic cancer to octreotide. Surgery, 120, 234-40;discussion 240.
10. Gandomkara M, Najafia R, Ebrahimib SE, Shafieeb A, Babaeia MH, Rabbanic M, Shabania GA. (2003). Direct labelling of octreotide with 99mTc: effect of different concentration of reducing agents and amount of sodium pertechnetate on radiolabelling efficiency. Applied Radiation and Isotopes, 58, 361-364.
11. Gencosmanoglu R, Bugra D, Bulut T, Yamaner S, Cevikbas U, Bilir A. (2002). The inhibitory effect of octreotide on experimental colorectal carcinogenesis. Surg Today, 32, 249-256. (Pubitemid 34280392)
12. Giannetti N, Enjalbert A, Krantic S. (2000). Somatostatin analog SMS 201995 inhibits proliferation in human leukemia T-cell line: relevance of the adenylyl cyclase stimulation. J Cell Biochem, 78, 666-673. (Pubitemid 30620711)
13. Gou M, Zheng X, Men K, Zhang J, Wang B, Lv L, Wang X, Zhao Y, Luo F, Chen L, Zhao X, Wei Y, Qian Z. (2009). Self-assembled hydrophobic honokiol loaded MPEG-PCL diblock copolymer micelles. Pharm Res, 26, 2164-2173.
14. Gou M, Shi H, Guo G, Men K, Zhang J, Zheng L, Li Z, Luo F, Qian Z, Zhao X, Wei Y. (2011a). Improving anticancer activity and reducing systemic toxicity of doxorubicin by self-assembled polymeric micelles. Nanotechnology, 22, 095102.
15. Gou ML, Men K, Shi H, Xiang M, Zhang J, Song J, Long J, Wan Y, Luo F, Zhao X, Qian Z. (2011b). Curcumin-loaded biodegradable polymeric micelles for colon cancer therapy in vitro and in vivo. Nanoscale, 3, 1558-1567.
16. Greenlee RT, Murray T, Bolden S, Wingo PA. (2000). Cancer Statistics, CA Cancer J Clin, 50, 7-33.
17. Herrmann J, Bodmeier R. (1995). Somatostatin containing biodegradable microspheres prepared by a modified solvent evaporation method based on W/O/W-multiple emulsions. International Journal of Pharmaceutics, 126, 129-138. (Pubitemid 26015630)
18. Herrmann J, Bodmeier R. (1998). Biodegradable, somatostatin acetate containing microspheres prepared by various aqueous and non-aqueous solvent evaporation methods. Eur J Pharm Biopharm, 45, 75-82. (Pubitemid 28248258)
19. Hsing PH, Ying TW. (1999). Direct Solid-Phase Synthesis of Octreotide Conjugates: Precursors for Use as Tumor-Targeted Radiopharmaceuticals. Bioorganic & Medicinal Chemistry, 7, 1797-1803.
20. Jeon HJ, Jeong YI, Jang MK, Park YH, Nah JW. (2000). Effect of solvent on the preparation of surfactant-free poly(DL-lactide-co-glycolide) nanoparticles and norfloxacin release characteristics. Int J Pharm, 207, 99-108.
21. Kerleta V, Andrlik I, Schneider M, Franke T, Wirth M, Gabor F. (2009) Pluronic® F-68 Enhances the Nanoparticle-Cell Interaction. Presented at the 21st Scientific Congress of the Austrian Pharmaceutical Society April 16th to April 18th 2009, Vienna, Austria. Conference abstract SL-12; Sci Pharm, 77, 179, SL-12
22. Kim KY. (2007). Nanotechnology platforms and physiological challenges for cancer therapeutics. Nanomedicine, 3, 103-110.
23. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, van Hagen M, Postema PT, de Jong M, Reubi JC. (1993). Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med, 20, 716-731. (Pubitemid 23284773)
24. Lamberts SW, Krenning EP, Reubi JC. (1991). The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev, 12, 450-482.
25. Lee JU, Hosotani R, Wada M, Doi R, Koshiba T, Fujimoto K, Miyamoto Y, Tsuji S, Nakajima S, Hirohashi M, Uehara T, Arano Y, Fujii N, Imamura M. (2002). Antiproliferative activity induced by the somatostatin analogue, TT-232, in human pancreatic cancer cells. Eur J Cancer, 38, 1526-1534. (Pubitemid 34756406)
26. Lewis DH, Chasin M, Langer R. (1990). Biodegradable polymers as drug delivery systems. New York: Marcel Dekker, 1-41.
27. Liebow C, Reilly C, Serrano M, Schally AV. (1989). Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc Natl Acad Sci USA, 86, 2003-2007. (Pubitemid 19087056)
28. Marschke RF Jr, Grill JP, Sloan JA, Wender DB, Levitt R, Mailliard JA, Gerstner JB, Ghosh C, Morton RF, Jett JR. (1999). Phase II study of high-dose somatostatin analogue in patients either previously treated or untreated who have extensive-stage small cell lung cancer. Am J Clin Oncol, 22, 15-17. (Pubitemid 30261582)
29. Morse MA, Stoner GD. (1993). Cancer chemoprevention: principles and prospects. Carcinogenesis, 14, 1737-1746. (Pubitemid 23290882)
30. Mu L, Feng SS. (2002). Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol). J Control Release, 80, 129-144. (Pubitemid 34273754)
31. Müller RH, Mäder K, Gohla S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm, 50, 161-177. (Pubitemid 30326695)
32. Murty SB, Goodman J, Thanoo BC, DeLuca PP. (2003). Identification of chemically modified peptide from poly(D,L-lactide-coglycolide) microspheres under in vitro release conditions. AAPS PharmSciTech, 4, E50.
33. Pollak MN, Schally AV. (1998). Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc Exp Biol Med, 217, 143-152.
34. Radulovic S, Comaru-Schally AM, Milovanovic S, Schally AV. (1993). Somatostatin analogue RC-160 and LH-RH antagonist SB-75 inhibit growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice. Pancreas, 8, 88-97. (Pubitemid 23005582)
35. Raynor K, Reisine T. (1993). Characterization of cloned somatostatin receptors SSTR4 and SSTR5. Am. Soc. Pharmacol Exp Ther, 16, 385-392. (Pubitemid 23252245)
36. Reichlin S. (1983). Somatostatin. N Engl J Med, 309, 1495-1501.
37. Scarpignato C, Pelosini I. (2001). Somatostatin analogs for cancer treatment and diagnosis: an overview. Chemotherapy, 47 Suppl 2, 1-29.
38. Schally AV. (1988). Oncological applications of somatostatin analogues. Cancer Res, 48, 6977-6985.
39. Setyono-Han B, Henkelman MS, Foekens JA, Klijn GM. (1987). Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells. Cancer Res, 47, 1566-1570. (Pubitemid 17044484)
40. Shan G, Bao-Ping Y, Yan L, Wei-Guo D, He-Sheng L. (2003). Antiproliferative effect of octreotide on gastric cancer cells mediated by inhibition of Akt/PKB and telomerase. World Journal of Gastroenterology, 9, 2362-2365.
41. Shenoy DB, Amiji MM. (2005). Poly(ethylene oxide)-modified poly(epsilon-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. Int J Pharm, 293, 261-270. (Pubitemid 40381098)
42. Simpkins H, Parekh H. (1996).Species-specific differences in taxol transport and cytotoxicity against human and rodent tumor cells. Biochem Pharmacol, 51, 301-311.
43. Van Cutsem E, Fevery J. (1995). Pancreatic cancer: a plea for more trials. Eur J Cancer, 31A, 867-869.
44. Von Hoff DD, Goodwin AL, Garcia L. (1998). Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team. Br J Cancer, 78 Suppl 3, 9-13.
45. Wei X, Gong C, Gou M, Fu S, Guo Q, Shi S, Luo F, Guo G, Qiu L, Qian Z. (2009). Biodegradable poly(epsilon-caprolactone)-poly(ethylene glycol) copolymers as drug delivery system. Int J Pharm, 381, 1-18.
46. Wenger FA, Kilian M, Mautsch I, Jacobi CA, Steiert A, Peter FJ, Guski H, Schimke I, Müller JM. (2001). Influence of octreotide on liver metastasis and hepatic lipid peroxidation in BOP-induced pancreatic cancer in Syrian hamsters. Pancreas, 23, 266-272. (Pubitemid 32910975)
47. Yuen MF, Poon RT, Lai CL, Fan ST, Lo CM, Wong KW, Wong WM, Wong BC. (2002). A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology, 36, 687-691. (Pubitemid 34977180)